21.91

5.18% -1.235

Beam Therapeutics Inc (BEAM)

Overview News Price History Option Chain Financials Why BEAM Down? Discussions Forecast

Beam Therapeutics Inc stock is traded at $21.91, with a volume of 770.23K. It is down -5.18% in the last 24 hours and down -12.65% over the past month. Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Previous Close:

$23.15

Open:

$22.12

24h Volume:

770.23K

Relative Volume:

0.29

Market Cap:

$2.21B

Revenue:

$352.57M

Net Income/Loss:

$-143.01M

P/E Ratio:

-12.11

EPS:

-1.81

Net Cash Flow:

$-153.40M

1W Performance:

-12.24%

1M Performance:

-12.65%

6M Performance:

+35.29%

1Y Performance:

-15.90%

1-Day Range:

$21.70

$22.38

1-Week Range:

$21.70

$25.19

52-Week Range:

$13.53

$35.25

Beam Therapeutics Inc Stock (BEAM) Company Profile

Name

Beam Therapeutics Inc

Sector

Healthcare (1136)

Industry

Biotechnology (631)

Phone

857-327-8775

Address

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Employee

509

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

BEAM's Discussions on Twitter

Compare BEAM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BEAM Beam Therapeutics Inc	21.88	2.35B	352.57M	-143.01M	-153.40M	-1.81
VRTX Vertex Pharmaceuticals Inc	410.42	105.61B	11.74B	3.68B	3.50B	14.19
REGN Regeneron Pharmaceuticals Inc	645.18	67.99B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	431.87	58.19B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	844.01	52.40B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	186.07	39.60B	447.02M	-1.18B	-906.14M	-6.1812

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-09-25	Initiated	Jefferies	Buy
Mar-28-25	Upgrade	BofA Securities	Neutral → Buy
Mar-10-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform
Jan-29-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-06-24	Upgrade	Leerink Partners	Market Perform → Outperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jul-23-24	Initiated	H.C. Wainwright	Buy
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral
Dec-08-23	Downgrade	Jefferies	Buy → Hold
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform
Dec-13-22	Initiated	Citigroup	Buy
Jun-17-22	Initiated	BMO Capital Markets	Market Perform
Apr-28-22	Initiated	Credit Suisse	Neutral
Jan-05-22	Initiated	Guggenheim	Buy
Oct-19-21	Initiated	SVB Leerink	Outperform
Sep-24-21	Resumed	Stifel	Buy
Sep-10-21	Initiated	BofA Securities	Buy
May-11-21	Initiated	Redburn	Buy
May-04-21	Initiated	RBC Capital Mkts	Sector Perform
Mar-01-21	Downgrade	Barclays	Overweight → Equal Weight
Feb-16-21	Initiated	Wells Fargo	Overweight
Jan-29-21	Downgrade	JP Morgan	Overweight → Neutral
Jan-06-21	Initiated	Stifel	Hold
Aug-05-20	Initiated	William Blair	Outperform
Mar-02-20	Initiated	Barclays	Overweight
Mar-02-20	Initiated	JP Morgan	Overweight
Mar-02-20	Initiated	Jefferies	Buy
Mar-02-20	Initiated	Wedbush	Outperform

View All

Beam Therapeutics Inc Stock (BEAM) Latest News

04:41 AM

How Beam Therapeutics Inc. stock compares to market leadersJuly 2025 PreEarnings & Weekly Breakout Opportunity Watchlist - newser.com

04:41 AM

02:27 AM

Historical volatility pattern of Beam Therapeutics Inc. visualized2025 Price Action Summary & Verified Momentum Stock Ideas - newser.com

02:27 AM

Nov 06, 2025

Beam Therapeutics achieves top CGT award for BEAM-302 - Traders Union

Nov 06, 2025

Institutional scanner results for Beam Therapeutics Inc.2025 Key Highlights & Precise Buy Zone Tips - newser.com

Nov 06, 2025

What is the fair value of Beam Therapeutics Inc. stock nowJuly 2025 PreEarnings & Growth Focused Entry Point Reports - newser.com

Nov 06, 2025

What analyst consensus says on Beam Therapeutics Inc. stockJuly 2025 Price Swings & AI Based Buy and Sell Signals - newser.com

Nov 06, 2025

Why retail investors favor Beam Therapeutics Inc. stockJuly 2025 Update & Short-Term Swing Trade Alerts - newser.com

Nov 06, 2025

Nov 05, 2025

How buybacks impact Beam Therapeutics Inc. stock valueTrade Volume Report & Reliable Volume Spike Trade Alerts - newser.com

Nov 05, 2025

Real time social sentiment graph for Beam Therapeutics Inc.Trade Entry Summary & Reliable Volume Spike Trade Alerts - newser.com

Nov 05, 2025

Visual analytics tools that track Beam Therapeutics Inc. performanceLong Setup & Expert Verified Movement Alerts - newser.com

Nov 05, 2025

Beam Therapeutics Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo

Nov 05, 2025

January 2026 Options Now Available For Beam Therapeutics (BEAM) - Nasdaq

Nov 05, 2025

Beam Therapeutics (NASDAQ:BEAM) Releases Quarterly Earnings Results, Misses Estimates By $0.12 EPS - MarketBeat

Nov 05, 2025

How to monitor Beam Therapeutics Inc. with trend dashboardsMarket Trend Report & Weekly High Conviction Trade Ideas - newser.com

Nov 05, 2025

Beam Therapeutics’ BEACON Trial: A New Hope for Sickle Cell Disease - MSN

Nov 05, 2025

Should you wait for a breakout in Beam Therapeutics Inc.Market Risk Analysis & Scalable Portfolio Growth Methods - newser.com

Nov 05, 2025

Beam Therapeutics (BEAM): Losses Worsen as Profitability Remains Elusive Despite Rapid Revenue Growth Forecasts - Yahoo Finance

Nov 04, 2025

FMR LLC Reduces Stake in Beam Therapeutics Inc: A Strategic Move in the Biotech Sector - GuruFocus

Nov 04, 2025

(BEAM) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com

Nov 04, 2025